Company intelligence / Profile preview

Danco Laboratories

New York City, New York, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Mifepristone (Mifeprex), marketed by Danco Laboratories, is FDA-approved and over 5 million women in the US have used it since 2000 for early pregnancy termination. Extensive data indicates it is safe and effective, with less than 0.1% serious adverse events and negligible hospitalization rates[8][6][3][2][1].

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

Population Council (initial US rights transfer/licensing of mifepristone)Manufacturing agreement (historically with Gedeon Richter, current manufacturer undisclosed)

Beyond the preview

Go deeper on Danco Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Danco Laboratories.

Explore the full profile